3267 related articles for article (PubMed ID: 7669636)
1. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
Weiss J; Heine M; Körner B; Pilch H; Jung EG
Br J Dermatol; 1995 Jul; 133(1):23-31. PubMed ID: 7669636
[TBL] [Abstract][Full Text] [Related]
2. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
3. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis.
Lee CS; Pirdas A; Lee MW
Australas J Dermatol; 1995 Nov; 36(4):192-5. PubMed ID: 8593106
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 protein in melanoma progression.
Kanoko M; Ueda M; Nagano T; Ichihashi M
J Dermatol Sci; 1996 Jun; 12(2):97-103. PubMed ID: 8814540
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 over-expression in thin melanomas.
Sparrow LE; English DR; Heenan PJ; Dawkins HJ; Taran J
Melanoma Res; 1995 Dec; 5(6):387-92. PubMed ID: 8589612
[TBL] [Abstract][Full Text] [Related]
7. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
10. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
11. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
14. Expression of the p53 protein in malignant melanomas as a prognostic indicator.
Yamamoto M; Takahashi H; Saitoh K; Horikoshi T; Takahashi M
Arch Dermatol Res; 1995; 287(2):146-51. PubMed ID: 7763085
[TBL] [Abstract][Full Text] [Related]
15. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
16. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
17. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
19. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
